查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1854166

非类固醇消炎剂市场按药物类别、剂型、给药途径、製剂状态、释放类型、病患小组、适应症​​、最终用户和分销管道划分－2025-2032年全球预测

Non-steroidal Anti-inflammatory Drugs Market by Drug Class, Formulation, Route Of Administration, Prescription Status, Release Type, Patient Group, Indication, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，非类固醇消炎剂市场规模将达到 388.1 亿美元，复合年增长率为 6.67%。

关键市场统计数据
基准年2024年 231.4亿美元
预计年份：2025年 246.2亿美元
预测年份 2032 388.1亿美元
复合年增长率 (%) 6.67%

对影响非类固醇消炎剂临床应用、分销和生命週期管理的当前动态进行了清晰权威的介绍。

非类固醇消炎剂(NSAIDs) 在临床实践和消费者自我护理中仍然占据核心地位，这主要归因于全球持续存在的疼痛、发炎和慢性肌肉骨骼疾病负担。本文概述了 NSAIDs 市场格局的变化，并重点阐述了患者期望、监管审查和供应链压力如何相互作用，重塑产品开发和分销的格局。

过去几年，临床医生和患者对药物的安全性、长期耐受性以及疗效与副作用之间的权衡有了更深入的了解。同时，数位医疗平台和药局零售的创新正在拓展患者的就医途径，并改变他们的购买模式。因此，製造商和医疗服务提供者必须在实证治疗方法的选择与实际考虑（例如药物目录收录、报销趋势和实际用药依从性）之间取得平衡。为此，价值链上的相关人员在重新思考临床通讯、生命週期管理和分销策略，以满足不断变化的需求，同时确保合规性和品质标准。

技术进步、不断变化的法规以及患者期望的转变如何重塑非类固醇消炎剂领域的竞争策略和产品创新

非类固醇消炎剂市场正经历着由技术进步、监管变革和患者​​行为改变所驱动的重大变革。新型数位疗法和远端医疗正在改变诊疗和决策流程，为教育和处方管理开闢新的途径。同时，药物安全检测和真实世界证据收集的进步正在加强安全性评估，并为附加檔更新和处方指南的製定提供依据。

製造商正透过优先研发差异化配方、优化药物动力学特征以及投资以患者为中心的包装和依从性解决方案来应对挑战。同时，支付方和采购机构要求更清晰的价值主张，他们越来越关注总成本和疗效，而不仅仅是单价。此外，供应链多元化和本土化措施正在推动策略供应商关係的建立和库存优化。总而言之，这些因素正在重塑竞争格局，并加速配方、给药途径和渠道策略的创新。

评估累积关税调整对美国供应链采购、成本管理和商业性定位的营运和策略影响

2025年，美国累积关税调整给整个医药供应链带来了巨大的成本压力，影响了采购决策、定价策略和营运韧性。关税相关的成本增加会沿着价值链层层传递，促使製造商和经销商重新评估其供应商布局，协商修订供应商合同，并寻求替代原材料来源，以维持利润率和供应的连续性。

因此，企业采取了多种策略，包括整合拥有良好合规记录的供应商、加快二级供应商的资格审核，以及评估区域製造能力，以降低跨境关税的影响。这些调整促使企业更加重视总成本模型和库存规划，进而降低价格波动。同时，商务团队正加强与付款方和主要采购负责人的沟通，以明确成本驱动因素和价值差异化因素，从而为价格调整提供依据。展望未来，将关税敏感性纳入策略采购和情境规划的企业，将更有能力在保障财务绩效的同时，维持产品供应。

以细分市场主导的洞察，将分销管道、给药途径、药物类别、剂型和终端用户动态与策略决策点连结起来。

我们细緻入微的市场细分框架揭示了临床偏好、通路经济和製剂选择如何相互作用，从而影响产品的可行性和市场接受度。按分销管道划分，我们检视了非处方药和处方笺市场，并发现了不同的需求驱动因素：消费者自我护理的优先性决定了非处方药的市场份额，而临床指南和报销政策则决定了处方笺的使用。按给药途径划分，我们检视了口服、注射和外用市场，并揭示了给药途径如何影响安全性监测、病患依从性和製剂研发重点。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 推出一种新型缓释性Ibuprofen製剂，用于慢性疼痛管理
  • 非类固醇抗发炎药物与生物製药联合治疗的研发正在取得进展，该疗法旨在缓解发炎并减少副作用。
  • 扩大局部使用局部双氯芬酸钠凝胶治疗老年患者局部骨关节炎的适用范围
  • 推出人工智慧驱动的药物警戒平台，用于监测与非类固醇抗发炎药物使用相关的心血管风险
  • 为了提高患者在非处方药市场的依从性，固定剂量对乙酰胺酚和Ibuprofen的组合药物正在兴起。
  • 促进美洛昔康注射微球製剂在术后止痛的监管
  • 加大对绿色化学製程的投资，以实现永续製造
  • 随着加速术后恢復通讯协定的广泛采用，术中静脉注射非类固醇抗发炎药物以减少鸦片类药物的使用量增加。
  • 零售商在电子商务止痛药领域转向自有品牌和超值包装，导致Ibuprofen和萘普生的价格竞争加剧。
  • 将CYP2C9和CYP2C8变异体的药物遗传学检测纳入考量，以实现高风险患者非类固醇抗发炎药物的个人化选择和剂量。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章非类固醇消炎剂市场（依药物类别划分）

  • 乙酸衍生物
    • 双氯芬酸钠
    • Ketorolac
  • 费纳梅特
    • 氟芬那酸
    • 甲芬那酸
  • 奥昔康
    • Piroxicam
    • 替诺昔康
  • 丙酸衍生物
    • 氟比洛芬
    • Ibuprofen
    • 酮洛芬
    • 萘普生
  • 水杨酸盐
    • 阿斯匹灵
    • 二氟尼柳
  • 选择性COX-2抑制剂（昔布类药物）
    • 塞来昔布
    • 依托考昔

第九章 处方类非类固醇消炎剂市场

  • 胶囊
  • 乳霜/凝胶
  • 粉末
  • 药片

第十章非类固醇消炎剂市场依给药途径划分

  • 口服
  • 肠外
  • 话题

第十一章非类固醇消炎剂市场（依处方笺状态划分）

  • 在商店
  • 仅限处方笺

第十二章非类固醇消炎剂市场依释放类型划分

  • 即时释放
  • 改良释放
    • 控释
    • 延迟释放/肠溶包衣
    • 缓释性

第十三章非类固醇消炎剂市场病患小组

  • 成人
  • 老年人
  • 孩子们

第十四章非类固醇消炎剂市场依适应症划分

  • 急性疼痛
    • 牙痛
    • 肌肉骨骼损伤（扭伤/拉伤）
    • 术后疼痛
  • 僵直性脊椎炎
  • 月经
  • 发烧
  • 偏头痛
  • 眼痛和炎症
  • 骨关节炎
  • 类风湿性关节炎

第十五章非类固醇消炎剂市场（依最终用户划分）

  • 门诊手术中心
  • 居家照护
  • 医院
  • 专科诊所

第十六章非类固醇消炎剂市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药局

第十七章非类固醇消炎剂市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十八章非类固醇消炎剂市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十九章 各国非类固醇消炎剂市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第20章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Novartis AG
    • Bayer AG
    • Pfizer Inc.
    • Abbvie, Inc
    • Algen Healthcare Ltd.
    • Allegiant Health
    • Amgen Inc.
    • Amneal Pharmaceuticals LLC
    • Arcutis Biotherapeutics, Inc.
    • Astellas Pharma Inc.
    • AstraZeneca PLC
    • Bristol-Myers Squibb Company
    • Clearsynth Labs Limited
    • Genentech, Inc. by F. Hoffmann-La Roche AG
    • GlaxoSmithKline PLC
    • Johnson & Johnson Services, Inc.
    • Pharbest Pharmaceuticals, Inc.
    • Sanofi SA
    • Spectrum Chemical Mfg. Corp.
    • Sun Pharmaceutical Industries Ltd.
    • Teikoku Seiyaku Co., Ltd.
    • Boehringer Ingelheim GmbH
    • Daiichi Sankyo Company, Limited
    • Eisai Co., Ltd.
    • Gilead Sciences, Inc.
    • Eli Lilly and Company
    • Incyte Corporation
    • Merck KGaA
    • Takeda Pharmaceutical Co. Ltd.
    • Dr. Reddy's Laboratories Ltd.
    • Sandoz International GmbH
    • Viatris Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Verona Pharma plc
    • Hikma Pharmaceuticals PLC
    • EMS SA
    • BASF SE
Product Code: MRR-7C50F2739687

The Non-steroidal Anti-inflammatory Drugs Market is projected to grow by USD 38.81 billion at a CAGR of 6.67% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 23.14 billion
Estimated Year [2025] USD 24.62 billion
Forecast Year [2032] USD 38.81 billion
CAGR (%) 6.67%

A clear and authoritative introduction to the current dynamics influencing clinical use, distribution, and lifecycle management of non-steroidal anti-inflammatory drugs

Non-steroidal anti-inflammatory drugs (NSAIDs) continue to occupy a central role in clinical practice and consumer self-care, driven by a persistent global burden of pain, inflammation, and chronic musculoskeletal conditions. This introduction frames the evolving context in which NSAIDs operate, highlighting how patient expectations, regulatory scrutiny, and supply chain pressures intersect to reshape product development and distribution dynamics.

Over the past several years, clinicians and patients have grown more discerning about safety profiles, long-term tolerability, and the therapeutic trade-offs between efficacy and adverse effects. Concurrently, digital health platforms and pharmacy retail innovations have broadened access pathways and altered purchasing patterns. In turn, manufacturers and healthcare providers must balance evidence-based therapeutic selection with pragmatic considerations such as formulary positioning, reimbursement trends, and real-world adherence. As a result, stakeholders across the value chain are rethinking clinical messaging, lifecycle management, and distribution strategies to meet shifting demand while maintaining compliance and quality standards.

How technological advances, regulatory evolution, and shifting patient expectations are reshaping competitive strategies and product innovation in the NSAID arena

The landscape for non-steroidal anti-inflammatory drugs is undergoing transformative shifts driven by technology, regulatory evolution, and changes in patient behavior. Emerging digital therapeutics and telemedicine have altered the points of care and decision-making, creating new touchpoints for education and prescription management. At the same time, advances in pharmacovigilance and real-world evidence collection are elevating safety assessment and informing label updates and prescribing guidelines.

Manufacturers are responding by prioritizing differentiated formulations, refining pharmacokinetic profiles, and investing in patient-centric packaging and adherence solutions. In parallel, payers and procurement organizations are demanding clearer value propositions, which increasingly emphasize total cost of care and outcomes rather than unit price alone. Moreover, supply chain diversification and onshoring initiatives are prompting strategic supplier relationships and inventory optimization. Taken together, these forces are reshaping competitive positioning and accelerating innovation across formulation, route of administration, and channel strategies.

Assessing the operational and strategic repercussions of cumulative tariff adjustments on supply chain sourcing, cost management, and commercial positioning in the US context

In 2025, cumulative tariff adjustments within the United States introduced material cost pressures across pharmaceutical supply chains, influencing sourcing decisions, pricing strategies, and operational resilience. Tariff-related cost increases can cascade through the value chain, prompting manufacturers and distributors to reassess supplier footprints, negotiate revised supplier agreements, and explore alternative raw material sources to preserve margins and supply continuity.

Consequently, organizations have pursued a mix of tactics, including consolidating suppliers with robust compliance track records, accelerating qualification of secondary suppliers, and evaluating regional manufacturing capacities to reduce exposure to cross-border duties. These adjustments have prompted magnified focus on total landed cost models and inventory planning to buffer volatility. At the same time, commercial teams have intensified dialogue with payers and major purchasers to articulate cost drivers and value differentiators that justify pricing adjustments. Looking forward, firms that integrate tariff sensitivity into strategic procurement and scenario planning will be better positioned to maintain product availability while safeguarding financial performance.

Segment-driven insights that connect distribution channel, administration route, drug class, formulation types, and end-user dynamics to strategic decision points

A nuanced segmentation framework reveals where clinical preferences, channel economics, and formulation choices intersect to influence product viability and adoption. Based on Distribution Channel, the market is studied across Over The Counter and Prescription, highlighting divergent demand drivers where consumer self-care priorities shape OTC traction while clinical guidelines and reimbursement determine prescription utilization. Based on Route Of Administration, the market is studied across Oral, Parenteral, and Topical, underscoring how administration mode influences safety monitoring, patient adherence, and formulation development priorities.

Based on Drug Class, the market is studied across COX-2 Inhibitors and Nonselective COX Inhibitors, reflecting distinct efficacy and safety trade-offs that inform therapeutic positioning and regulatory scrutiny. Based on Formulation, the market is studied across Capsules, Creams, Gels, Powders, Suspensions, Tablets, and Transdermal Patches, each of which carries unique manufacturing, stability, and patient-preference implications. Based on End User, the market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, demonstrating how procurement cycles, dispensing protocols, and patient access differ by channel. Integrating these segmentation lenses reveals clear vectors for differentiation in R&D investment, marketing focus, and supply chain design, and it clarifies the levers that drive product uptake and clinical acceptance across diverse care settings.

Regional intelligence explaining how distinct regulatory frameworks, payer dynamics, and care models drive differentiated strategies across global geographies

Regional dynamics continue to shape regulatory approaches, reimbursement pathways, and adoption patterns for non-steroidal anti-inflammatory therapies, and a regionally attuned strategy is essential for commercial success. In the Americas, stakeholders navigate a complex interplay of payer-driven access controls, consolidated distribution networks, and high rates of consumer engagement with OTC analgesics, requiring tailored evidence generation and value communication. In Europe, Middle East & Africa, regulatory frameworks and healthcare financing models vary markedly across jurisdictions, which drives differentiated product registration strategies and localized evidence packages to meet heterogeneous standards and procurement processes.

In the Asia-Pacific region, demographic shifts toward aging populations, expanding primary care infrastructure, and strong growth in e-pharmacy adoption are converging to increase demand for both prescription and OTC NSAID formulations. Across all regions, local manufacturing capabilities, regulatory timelines, and supply chain resilience inform launch sequencing and portfolio prioritization. Therefore, commercial teams must align regional market access strategies with local clinical practice patterns and distribution realities, and they must invest in regulatory intelligence and stakeholder engagement to accelerate adoption while maintaining compliance.

Company-level strategies that prioritize supply reliability, product differentiation, and evidence-driven positioning to strengthen competitive advantage

Competitive dynamics in the NSAID space continue to favor organizations that combine reliable supply chains, clear safety messaging, and targeted clinical differentiation. Leading pharmaceutical companies are refining lifecycle strategies by extending formulations, pursuing novel delivery mechanisms, and investing in post-marketing safety studies that reinforce confidence among prescribers and patients. In addition, several firms are leveraging partnerships with specialty manufacturers and contract development organizations to accelerate time-to-market for value-added formulations, reduce capital intensity, and access technical expertise in transdermal and topical platforms.

Strategic alliances between branded manufacturers and retail or online pharmacy chains are becoming more prevalent to secure shelf placement and consumer visibility. At the same time, product stewardship and pharmacovigilance investments have become non-negotiable differentiators, particularly as regulators and payers demand robust real-world evidence to support ongoing approvals and label updates. Firms that demonstrate operational excellence, transparent safety data, and coherent value narratives will maintain stronger relationships with payers, clinicians, and distribution partners, and they will be better positioned to defend and extend commercial relevance.

Actionable strategic priorities and operational levers for industry leaders to mitigate risk, strengthen differentiation, and accelerate commercial performance

Industry leaders should act decisively to translate evolving dynamics into competitive advantage through targeted investments and operational refinement. Prioritize diversification of raw material and finished-goods sourcing to mitigate tariff exposure and geopolitical risk, and concurrently implement advanced scenario planning that quantifies the operational impact of supply disruptions. Enhance pharmacovigilance and real-world evidence generation programs to support safety narratives and to facilitate constructive engagement with regulators, payers, and prescribers.

Furthermore, accelerate investments in differentiated formulations and patient-centric delivery systems that address adherence challenges and unmet needs, and align commercial messaging to emphasize total therapeutic value rather than unit price. Strengthen partnerships with distribution channels-hospital systems, retail pharmacies, and online pharmacies-to secure preferred placement and to tailor promotional tactics to channel-specific buying behavior. Finally, embed sustainability and quality assurance into supplier selection and manufacturing practices to meet rising stakeholder expectations and to reduce long-term operational risk.

A transparent and reproducible research methodology combining primary stakeholder interviews and secondary evidence synthesis to support robust insights

The research underpinning this analysis combined structured primary interviews with a cross-section of stakeholders and rigorous secondary research across public regulatory filings, clinical literature, and industry publications. Primary engagements included discussions with clinicians, formulary decision-makers, procurement leads, and supply chain executives to surface practical challenges and decision criteria that influence adoption and procurement. Secondary sources were used to validate trends in prescribing behavior, regulatory updates, and distribution innovations, and to triangulate findings from primary interviews.

Analytical approaches included thematic synthesis of qualitative inputs, scenario-based supply chain modeling to assess tariff impacts, and comparative assessment of formulation and channel dynamics. Quality assurance processes involved cross-validation of key assertions with multiple sources and iterative review by subject-matter experts. This methodology ensured that strategic conclusions reflect real-world stakeholder priorities and that recommended actions are grounded in defensible evidence and operational feasibility.

Strategic conclusion emphasizing operational resilience, evidence-based differentiation, and aligned channel engagement to sustain competitive relevance

In conclusion, the NSAID landscape is in a period of pragmatic evolution rather than radical upheaval, with incremental shifts driven by regulatory emphasis on safety, changing care delivery models, and supply chain realignment. Manufacturers and commercial teams must navigate these changes with disciplined portfolio management, targeted formulation innovation, and enhanced engagement with payers and distribution partners. Stakeholders that integrate tariff sensitivity into procurement planning, invest in real-world safety evidence, and pursue patient-centric delivery formats will be better positioned to sustain relevance and meet clinician and consumer needs.

Moving forward, organizations should maintain a dual focus on near-term operational resilience and medium-term clinical differentiation. By harmonizing supply chain decisions with evidence generation and channel strategies, firms can reduce exposure to external shocks while creating durable competitive advantages. Ultimately, the most successful players will combine operational rigor with a clear articulation of clinical and economic value to secure trust among clinicians, payers, and patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Launch of novel extended-release subcutaneous ibuprofen formulations targeting chronic pain management
  • 5.2. Rising development of NSAID-biologic combination therapies to mitigate inflammation with reduced side effects
  • 5.3. Expansion of topical diclofenac gel adoption among geriatric patients for localized osteoarthritis relief
  • 5.4. Deployment of AI-driven pharmacovigilance platforms to monitor cardiovascular risks associated with NSAID usage
  • 5.5. Growth of fixed-dose paracetamol and ibuprofen co-formulations to improve patient adherence in over-the-counter markets
  • 5.6. Regulatory acceleration for injectable meloxicam microsphere formulations aimed at postoperative pain control
  • 5.7. Increasing investment in green chemistry processes for sustainable manufacturing of non-steroidal anti-inflammatory drugs
  • 5.8. Wider adoption of enhanced recovery after surgery protocols driving increased perioperative use of intravenous NSAIDs to reduce opioids
  • 5.9. Shift toward retailer private labels and value packs in e-commerce analgesics intensifying price competition for ibuprofen and naproxen
  • 5.10. Integration of pharmacogenetic testing for CYP2C9 and CYP2C8 variants to personalize NSAID choice and dosing in high-risk patients

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Non-steroidal Anti-inflammatory Drugs Market, by Drug Class

  • 8.1. Acetic Acid Derivatives
    • 8.1.1. Diclofenac
    • 8.1.2. Ketorolac
  • 8.2. Fenamates
    • 8.2.1. Flufenamic Acid
    • 8.2.2. Mefenamic Acid
  • 8.3. Oxicams
    • 8.3.1. Piroxicam
    • 8.3.2. Tenoxicam
  • 8.4. Propionic Acid Derivatives
    • 8.4.1. Flurbiprofen
    • 8.4.2. Ibuprofen
    • 8.4.3. Ketoprofen
    • 8.4.4. Naproxen
  • 8.5. Salicylates
    • 8.5.1. Aspirin
    • 8.5.2. Diflunisal
  • 8.6. Selective COX-2 Inhibitors (Coxibs)
    • 8.6.1. Celecoxib
    • 8.6.2. Etoricoxib

9. Non-steroidal Anti-inflammatory Drugs Market, by Formulation

  • 9.1. Capsules
  • 9.2. Creams/Gels
  • 9.3. Powders
  • 9.4. Tablets

10. Non-steroidal Anti-inflammatory Drugs Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Parenteral
  • 10.3. Topical

11. Non-steroidal Anti-inflammatory Drugs Market, by Prescription Status

  • 11.1. Over-The-Counter
  • 11.2. Prescription Only

12. Non-steroidal Anti-inflammatory Drugs Market, by Release Type

  • 12.1. Immediate-Release
  • 12.2. Modified-Release
    • 12.2.1. Controlled-Release
    • 12.2.2. Delayed-Release/Enteric-Coated
    • 12.2.3. Extended-Release

13. Non-steroidal Anti-inflammatory Drugs Market, by Patient Group

  • 13.1. Adults
  • 13.2. Geriatric
  • 13.3. Pediatric

14. Non-steroidal Anti-inflammatory Drugs Market, by Indication

  • 14.1. Acute Pain
    • 14.1.1. Dental Pain
    • 14.1.2. Musculoskeletal Injury (Sprain/Strain)
    • 14.1.3. Postoperative Pain
  • 14.2. Ankylosing Spondylitis
  • 14.3. Dysmenorrhea
  • 14.4. Fever/Pyrexia
  • 14.5. Migraine & Headache
  • 14.6. Ophthalmic Pain & Inflammation
  • 14.7. Osteoarthritis
  • 14.8. Rheumatoid Arthritis

15. Non-steroidal Anti-inflammatory Drugs Market, by End User

  • 15.1. Ambulatory Surgical Centers
  • 15.2. Homecare
  • 15.3. Hospitals
  • 15.4. Specialty Clinics

16. Non-steroidal Anti-inflammatory Drugs Market, by Distribution Channel

  • 16.1. Hospital Pharmacies
  • 16.2. Online Pharmacies
  • 16.3. Retail Pharmacies

17. Non-steroidal Anti-inflammatory Drugs Market, by Region

  • 17.1. Americas
    • 17.1.1. North America
    • 17.1.2. Latin America
  • 17.2. Europe, Middle East & Africa
    • 17.2.1. Europe
    • 17.2.2. Middle East
    • 17.2.3. Africa
  • 17.3. Asia-Pacific

18. Non-steroidal Anti-inflammatory Drugs Market, by Group

  • 18.1. ASEAN
  • 18.2. GCC
  • 18.3. European Union
  • 18.4. BRICS
  • 18.5. G7
  • 18.6. NATO

19. Non-steroidal Anti-inflammatory Drugs Market, by Country

  • 19.1. United States
  • 19.2. Canada
  • 19.3. Mexico
  • 19.4. Brazil
  • 19.5. United Kingdom
  • 19.6. Germany
  • 19.7. France
  • 19.8. Russia
  • 19.9. Italy
  • 19.10. Spain
  • 19.11. China
  • 19.12. India
  • 19.13. Japan
  • 19.14. Australia
  • 19.15. South Korea

20. Competitive Landscape

  • 20.1. Market Share Analysis, 2024
  • 20.2. FPNV Positioning Matrix, 2024
  • 20.3. Competitive Analysis
    • 20.3.1. Novartis AG
    • 20.3.2. Bayer AG
    • 20.3.3. Pfizer Inc.
    • 20.3.4. Abbvie, Inc
    • 20.3.5. Algen Healthcare Ltd.
    • 20.3.6. Allegiant Health
    • 20.3.7. Amgen Inc.
    • 20.3.8. Amneal Pharmaceuticals LLC
    • 20.3.9. Arcutis Biotherapeutics, Inc.
    • 20.3.10. Astellas Pharma Inc.
    • 20.3.11. AstraZeneca PLC
    • 20.3.12. Bristol-Myers Squibb Company
    • 20.3.13. Clearsynth Labs Limited
    • 20.3.14. Genentech, Inc. by F. Hoffmann-La Roche AG
    • 20.3.15. GlaxoSmithKline PLC
    • 20.3.16. Johnson & Johnson Services, Inc.
    • 20.3.17. Pharbest Pharmaceuticals, Inc.
    • 20.3.18. Sanofi S.A.
    • 20.3.19. Spectrum Chemical Mfg. Corp.
    • 20.3.20. Sun Pharmaceutical Industries Ltd.
    • 20.3.21. Teikoku Seiyaku Co., Ltd.
    • 20.3.22. Boehringer Ingelheim GmbH
    • 20.3.23. Daiichi Sankyo Company, Limited
    • 20.3.24. Eisai Co., Ltd.
    • 20.3.25. Gilead Sciences, Inc.
    • 20.3.26. Eli Lilly and Company
    • 20.3.27. Incyte Corporation
    • 20.3.28. Merck KGaA
    • 20.3.29. Takeda Pharmaceutical Co. Ltd.
    • 20.3.30. Dr. Reddy's Laboratories Ltd.
    • 20.3.31. Sandoz International GmbH
    • 20.3.32. Viatris Inc.
    • 20.3.33. Teva Pharmaceutical Industries Ltd.
    • 20.3.34. Verona Pharma plc
    • 20.3.35. Hikma Pharmaceuticals PLC
    • 20.3.36. EMS S.A.
    • 20.3.37. BASF SE

LIST OF FIGURES

  • FIGURE 1. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 17. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 19. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. MIDDLE EAST NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. ASEAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. GCC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. EUROPEAN UNION NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. BRICS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 34. G7 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 35. NATO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 36. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 37. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 38. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DICLOFENAC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DICLOFENAC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DICLOFENAC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DICLOFENAC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DICLOFENAC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DICLOFENAC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOROLAC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOROLAC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOROLAC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOROLAC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOROLAC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOROLAC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLUFENAMIC ACID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLUFENAMIC ACID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLUFENAMIC ACID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLUFENAMIC ACID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLUFENAMIC ACID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLUFENAMIC ACID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MEFENAMIC ACID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MEFENAMIC ACID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MEFENAMIC ACID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MEFENAMIC ACID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MEFENAMIC ACID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MEFENAMIC ACID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PIROXICAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PIROXICAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PIROXICAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PIROXICAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PIROXICAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PIROXICAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TENOXICAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TENOXICAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TENOXICAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TENOXICAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TENOXICAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TENOXICAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLURBIPROFEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLURBIPROFEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLURBIPROFEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLURBIPROFEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLURBIPROFEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLURBIPROFEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IBUPROFEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IBUPROFEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IBUPROFEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IBUPROFEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IBUPROFEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOPROFEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOPROFEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOPROFEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOPROFEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOPROFEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOPROFEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY NAPROXEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY NAPROXEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY NAPROXEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY NAPROXEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY NAPROXEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ASPIRIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ASPIRIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ASPIRIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ASPIRIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ASPIRIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ASPIRIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DIFLUNISAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DIFLUNISAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DIFLUNISAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DIFLUNISAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DIFLUNISAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DIFLUNISAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CELECOXIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CELECOXIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CELECOXIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CELECOXIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CELECOXIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CELECOXIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ETORICOXIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ETORICOXIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ETORICOXIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ETORICOXIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ETORICOXIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ETORICOXIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CREAMS/GELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CREAMS/GELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CREAMS/GELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CREAMS/GELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CREAMS/GELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CREAMS/GELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POWDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POWDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POWDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POWDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POWDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION ONLY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION ONLY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION ONLY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION ONLY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION ONLY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION ONLY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IMMEDIATE-RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IMMEDIATE-RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IMMEDIATE-RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IMMEDIATE-RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IMMEDIATE-RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IMMEDIATE-RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CONTROLLED-RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CONTROLLED-RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CONTROLLED-RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CONTROLLED-RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CONTROLLED-RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CONTROLLED-RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DELAYED-RELEASE/ENTERIC-COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DELAYED-RELEASE/ENTERIC-COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DELAYED-RELEASE/ENTERIC-COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DELAYED-RELEASE/ENTERIC-COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DELAYED-RELEASE/ENTERIC-COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DELAYED-RELEASE/ENTERIC-COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY EXTENDED-RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY EXTENDED-RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY EXTENDED-RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY EXTENDED-RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY EXTENDED-RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY EXTENDED-RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DENTAL PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DENTAL PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DENTAL PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DENTAL PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DENTAL PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DENTAL PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MUSCULOSKELETAL INJURY (SPRAIN/STRAIN), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MUSCULOSKELETAL INJURY (SPRAIN/STRAIN), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MUSCULOSKELETAL INJURY (SPRAIN/STRAIN), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MUSCULOSKELETAL INJURY (SPRAIN/STRAIN), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MUSCULOSKELETAL INJURY (SPRAIN/STRAIN), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLO